SCHEMBL889593

SCHEMBL889593

CC[C@H]1O[C@@H](n2cc(C)c(=O)[nH]c2=O)CC1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 4/20 0.54
TK1 P04183 7/20 0.51
RNASE1 P07998 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14788961 1.00 TOP2A (0.54) TOP2ATK1RNASE1
SCHEMBL10079072 1.00 TOP2A (0.54) TOP2ATK1RNASE1
SCHEMBL15354282 0.91 RNASE1 (0.62) TK1RNASE1
SCHEMBL8906737 0.91 TK1 (0.57) TOP2ATK1RNASE1
SCHEMBL8905506 0.91 TOP2A (0.54) TOP2ATK1RNASE1
SCHEMBL24059145 0.91 RNASE1 (0.62) TK1RNASE1
SCHEMBL24059196 0.91 RNASE1 (0.62) TK1RNASE1
SCHEMBL2056757 0.91 RNASE1 (0.62) TK1RNASE1
SCHEMBL733403 0.91 RNASE1 (0.62) TK1RNASE1
SCHEMBL8905500 0.91 TOP2A (0.54) TOP2ATK1RNASE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230264164-A1 HOMOPOLYMER ENCODED NUCLEIC ACID MEMORY TRILINK BIOTECHNOLOGIES, LLC 2023-08-24 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
WO-2021234459-A9 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2022-02-03 WO disclosed
WO-2021234459-A2 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2021-11-25 WO disclosed
US-8969535-B2 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing LASERGEN, INC. (US) 2015-03-03 US disclosed
US-20130072388-A1 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING AGILENT TECHNOLOGIES, INC. 2013-03-21 US disclosed
US-8361727-B2 3′OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing LASERGEN, INC. (US) 2013-01-29 US disclosed
US-20110287427-A1 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN, INC. (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072388-A1 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING UNG, NT5C3B, OGG1 TOP2A 201/4885TK1 62/4885RNASE1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.